Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Galbraith

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
NMR in Biomedicine|September 21, 2006
MR in oncology drug developmentSusan M Galbraith
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2009
Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignanciesLinda M Velasquez, Ronald Boellaard, Georgia Kollia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2003
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic resultsGordon J S Rustin, Susan M Galbraith, Helen Anderson, et al.
NMR in Biomedicine|March 1, 2002
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysisSusan M Galbraith, Martin A Lodge, N Jane Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imagingSusan M Galbraith, Gordon J S Rustin, Martin A Lodge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2003
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imagingSusan M Galbraith, Ross J Maxwell, Martin A Lodge, et al.
Cancer Research|December 25, 2002
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculaturePeter D Davis, Graeme J Dougherty, David C Blakey, et al.
Molecular Cancer Therapeutics|June 23, 2021
Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical DevelopmentSonja J Gill, Paul W G Wijnhoven, Jacqueline H L Fok, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
NMR in Biomedicine|September 21, 2006
MR in oncology drug developmentSusan M Galbraith
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2009
Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignanciesLinda M Velasquez, Ronald Boellaard, Georgia Kollia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2003
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic resultsGordon J S Rustin, Susan M Galbraith, Helen Anderson, et al.
NMR in Biomedicine|March 1, 2002
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysisSusan M Galbraith, Martin A Lodge, N Jane Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imagingSusan M Galbraith, Gordon J S Rustin, Martin A Lodge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2003
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imagingSusan M Galbraith, Ross J Maxwell, Martin A Lodge, et al.
Cancer Research|December 25, 2002
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculaturePeter D Davis, Graeme J Dougherty, David C Blakey, et al.
Molecular Cancer Therapeutics|June 23, 2021
Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical DevelopmentSonja J Gill, Paul W G Wijnhoven, Jacqueline H L Fok, et al.
Pageof 1